TD Cowen analyst Charles Rhyee lowered the firm’s price target on Amwell (AMWL) to $5 from $7 and keeps a Hold rating on the shares. The firm said Q4 EBITDA was a solid beat andd reaffirming EBITDA for 2026 is encouraging but the 20% revenue decline guidance is concerning.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell price target lowered to $5 from $6 at Stifel
- Amwell: Cost Controls and Margin Gains Offset by Weak Growth Outlook, Justifying a Hold Rating
- American Well: Strong Near-Term Performance but Limited Post-2026 Visibility Keeps Rating at Hold
- Amwell reports Q4 EPS ($1.52), consensus ($1.60)
- Amwell sees Q1 revenue $48M-53M, consensus $57.82M